Cargando…
BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia
Chronic myeloid leukemia (CML) is induced by the oncogenic BCR-ABL1 tyrosine kinase and can be effectively treated for many years with tyrosine kinase inhibitors (TKIs). However, unless CML patients receive life-long TKI treatment, leukemia will eventually recur; this is attributed to the failure of...
Autores principales: | Hurtz, Christian, Hatzi, Katerina, Cerchietti, Leandro, Braig, Melanie, Park, Eugene, Kim, Yong-mi, Herzog, Sebastian, Ramezani-Rad, Parham, Jumaa, Hassan, Müller, Martin C., Hofmann, Wolf-Karsten, Hochhaus, Andreas, Ye, B. Hilda, Agarwal, Anupriya, Druker, Brian J., Shah, Neil P., Melnick, Ari M., Müschen, Markus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3201200/ https://www.ncbi.nlm.nih.gov/pubmed/21911423 http://dx.doi.org/10.1084/jem.20110304 |
Ejemplares similares
-
BCL6 enables Ph(+) acute lymphoblastic leukemia cells to survive BCR-ABL1 kinase inhibition
por: Duy, Cihangir, et al.
Publicado: (2011) -
BCL6 is critical for the development of a diverse primary B cell repertoire
por: Duy, Cihangir, et al.
Publicado: (2010) -
Rationale for targeting BCL6 in MLL-rearranged acute lymphoblastic leukemia
por: Hurtz, Christian, et al.
Publicado: (2019) -
Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma
por: Dupont, Thibault, et al.
Publicado: (2015) -
The transcriptional modulator BCL6 as a molecular target for breast cancer therapy
por: Walker, Sarah R., et al.
Publicado: (2014)